MODERNA INC.

ISIN: US60770K1079 WKN: 60770K107 Asset Class: Stock

2021/01/21 22:00:01

Price
132.98
USD

Difference
6.27%(7.84)

175.00 150.00 100.00 75.00 50.00 25.00 0.00 02.2020 04.2020 06.2020 08.2020 10.2020 12.2020

Contact Details

MODERNA INC. Tel: +1-617-714-6500 Lavina Talukdar Fax: +1-617-583-1998

Technology Square 200 Web:

https://www.modernatx.com/

E-mail: IR@modernatx.com

02139 Cambridge, Massachusetts

Company Profile

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

| Fixed assets | - | | - | | - | |
|--------------------------------|---------------|---------------|---------------|---------------|---|---|
| Equity capital of a company | | 1,174,800,000 | | 1,530,200,000 | | - |
| Cash and cash equivalents | 235,900,000 | | 658,400,000 | | - | |
| Accrued liabilities | | 67,700,000 | | 79,100,000 | | - |
| Other assets | - | | - | | - | |
| Current liabilities | | 143,100,000 | | 222,800,000 | | - |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | - | | - | | - |
| Different income | | 202,300,000 | | 274,500,000 | | - |
| Other liabilities | | - | | - | | - |
| Total assets | 1,589,400,000 | 1,589,400,000 | 1,962,100,000 | 1,962,100,000 | - | - |

| Balance notes | | | |
|---------------------|---------|---------|---------|
| | 2019 | 2018 | 2017 |
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 830 | 760 | - |
| Equity ratio | 73.91% | 77.99% | -% |
| Debt-equity ratio | 35.29% | 28.23% | -% |

| Others | | | |
|------------------|-------|--------|------|
| | 2019 | 2018 | 2017 |
| Tax Expense Rate | 0.14% | -0.08% | -% |

MODERNA INC.

ISIN: US60770K1079 WKN: 60770K107 Asset Class: Stock

| 2019 | 2018 | 2017 |
|--------------|---|---|
| 60,200,000 | 135,100,000 | - |
| -514,000,000 | -384,700,000 | - |
| -458,049,600 | -340,639,200 | - |
| -514,700,000 | -384,400,000 | - |
| -459,000,000 | -330,900,000 | - |
| 38,500,000 | 27,000,000 | - |
| 496,300,000 | 454,100,000 | - |
| -700,000 | 300,000 | - |
| - | - | - |
| 60,055 | 147,188 | - |
| | 60,200,000 -514,000,000 -458,049,600 -514,700,000 -459,000,000 38,500,000 496,300,000 | 60,200,000 135,100,000 -514,000,000 -384,700,000 -458,049,600 -340,639,200 -514,700,000 -384,400,000 -459,000,000 -330,900,000 38,500,000 27,000,000 496,300,000 454,100,000 -700,000 300,000 |

Board of Directors

| Members of Management Board | | |
|-----------------------------|--------------------------------|--|
| | | |
| Noubar Afeyan | Chairman of Board of Directors | |
| Stephen Berenson | Member of Board of Directors | |
| Sandra Horning, M.D. | Member of Board of Directors | |
| Robert Langer | Member of Board of Directors | |
| Paul Sagan | Member of Board of Directors | |
| François Nader, M.D. | Member of Board of Directors | |
| Elizabeth Tallett | Member of Board of Directors | |
| Stéphane Bancel | Chairman of Managing Board | |
| Tracey Franklin | Member of Executive Committee | |
| Stephen Hoge, M.D. | Member of Executive Committee | |
| Ray Jordan | Member of Executive Committee | |
| Marcello Damiani | Member of Executive Committee | |
| Lori Henderson | Member of Executive Committee | |
| Juan Andres | Member of Executive Committee | |
| David Meline | Member of Executive Committee | |
| Tal Zaks | Member of Executive Committee | |